Ken-Ichi Nibu1, Ryuichi Hayashi2, Takahiro Asakage3, Hiroya Ojiri4, Yoshihiro Kimata5, Takeshi Kodaira6, Toshitaka Nagao7, Torahiko Nakashima8, Takashi Fujii9, Hirofumi Fujii10, Akihiro Homma11, Kazuto Matsuura12, Nobuya Monden13, Takeshi Beppu14, Nobuhiro Hanai15, Tadaaki Kirita16, Yuzuru Kamei17, Naoki Otsuki18, Naomi Kiyota19, Sadamoto Zenda20, Ken Omura21, Koichi Omori19, Tetsuo Akimoto22, Kazuyoshi Kawabata23, Seiji Kishimoto24, Hiroya Kitano25, Iwai Tohnai26, Takashi Nakatsuka8. 1. Department of Otolarygology-Head and Neck Surgery, Kobe University Graduate School of Medicine, Japan. Electronic address: nibu@med.kobe-u.ac.jp. 2. Department of Head and Neck Surgery, National Cancer Center Hospital East, Japan. 3. Department of Head and Neck Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Japan. 4. Department of Radiology, Jikei University School of Medicine, Japan. 5. Department of Plastic and Reconstructive Surgery, Okayama University Graduate School of Medicine and Dentistry, Japan. 6. Department of Radiation Oncology, Aichi Cancer Center Hospital, Japan. 7. Department of Anatomic Pathology, Tokyo Medical University, Japan. 8. Department of Otolaryngology, Kyushu Medical Center, Japan. 9. Department of Otolaryngology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan. 10. Department of Clinical Oncology, Jichi Medical University, Japan. 11. Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Graduate School of Medicine, Japan. 12. Department of Head and Neck Surgery, Miyagi Cancer Center, Japan. 13. Department of Head and Neck Surgery, Shikoku Cancer Center, Japan. 14. Division of Head and Neck Surgery, Saitama Cancer Center, Japan. 15. Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Japan. 16. Department of Oral and Maxillofacial Surgery, Nara Medical University, Japan. 17. Department of Plastic and reconstructive Surgery, Nagoya University Graduate School of Medicine, Japan. 18. Department of Medical Oncology/Hematology, Kobe University Hospital, Japan. 19. Department of Radiation Oncology, National Cancer Center Hospital East, Japan. 20. Department of Oral and Maxillofacial Surgery, Graduate School of Dentistry, Tokyo Medical and Dental University, Japan. 21. Department of Otolaryngology-Head and Neck Surgery, Kyoto University Graduate School of Medicine, Japan. 22. Department of Head and Neck Oncology, Japanese Foundation for Cancer Research, Cancer Institute Hospital, Japan. 23. Department of Head and Neck Surgery, Kameda General Center, Japan. 24. Department of Otolaryngology-Head and Neck Surgery, Tottori University Graduate School of Medicine, Japan. 25. Department of Oral and Maxillofacial Surgery, Yokohama City University Graduate School of Medicine, Japan. 26. Department of Plastic, Reconstructive and Aesthetic Surgery, Saitama Medical University, Japan.
Abstract
OBJECTIVE: The first revision of "Japanese Clinical Practice Guideline for Head and Neck Cancer" was made in 2013 by the clinical practice guideline committee of Japan Society for Head and Neck Cancer, in response to the revision of the TNM classification. METHODS: 34 CQs (Clinical Questions) were newly adopted to describe the diagnosis and treatment methods currently considered most appropriate, and offered recommendation grade made by the consensus of the committee. A comprehensive literature search was performed for studies published between 2001 and 2012 using PubMed. Qualified studies were analyzed and the results were evaluated, consolidated and codified by all the committee members. RESULTS: Elective neck dissection (ND) does contribute to improvement in survival and should be performed for patients with high-risk tongue cancer. At present, no research has clearly demonstrated the utility of superselective arterial infusion chemotherapy. However, depending on the site and stage of the cancer, combination with radiotherapy may be useful for preserving organ function or improving survival rate. Concurrent CDDP chemotherapy and adjuvant radiotherapy contributes to improvement of survival rate as an adjuvant therapy for advanced squamous cell carcinoma of the head and neck in patients at high risk of recurrence. The anti-EGFR antibody cetuximab (Cmab) has an additive effect with radiotherapy. However, the indication must be carefully considered since this treatment has not been compared with the standard treatment of chemoradiotherapy. Cmab has been shown to have an additive effect with chemotherapy (CDDP/5-FU) in patients with unresectable metastatic or recurrent cancer. Preoperative and postoperative oral care may reduce the risk of postoperative complications such as surgical wound infection and pneumonia in head and neck cancers. Rehabilitation soon after ND for cervical lymph node metastasis is recommended for maintaining and restoring shoulder function. CONCLUSIONS: In this article, we described most relevant guidelines and CQs for the diagnosis and treatment of head and neck cancer in Japan. These guidelines are not intended to govern therapies that are not shown here, but rather aim to be used as a guide in searching for the most appropriate treatment for individual patient.
OBJECTIVE: The first revision of "Japanese Clinical Practice Guideline for Head and Neck Cancer" was made in 2013 by the clinical practice guideline committee of Japan Society for Head and Neck Cancer, in response to the revision of the TNM classification. METHODS: 34 CQs (Clinical Questions) were newly adopted to describe the diagnosis and treatment methods currently considered most appropriate, and offered recommendation grade made by the consensus of the committee. A comprehensive literature search was performed for studies published between 2001 and 2012 using PubMed. Qualified studies were analyzed and the results were evaluated, consolidated and codified by all the committee members. RESULTS: Elective neck dissection (ND) does contribute to improvement in survival and should be performed for patients with high-risk tongue cancer. At present, no research has clearly demonstrated the utility of superselective arterial infusion chemotherapy. However, depending on the site and stage of the cancer, combination with radiotherapy may be useful for preserving organ function or improving survival rate. Concurrent CDDP chemotherapy and adjuvant radiotherapy contributes to improvement of survival rate as an adjuvant therapy for advanced squamous cell carcinoma of the head and neck in patients at high risk of recurrence. The anti-EGFR antibody cetuximab (Cmab) has an additive effect with radiotherapy. However, the indication must be carefully considered since this treatment has not been compared with the standard treatment of chemoradiotherapy. Cmab has been shown to have an additive effect with chemotherapy (CDDP/5-FU) in patients with unresectable metastatic or recurrent cancer. Preoperative and postoperative oral care may reduce the risk of postoperative complications such as surgical wound infection and pneumonia in head and neck cancers. Rehabilitation soon after ND for cervical lymph node metastasis is recommended for maintaining and restoring shoulder function. CONCLUSIONS: In this article, we described most relevant guidelines and CQs for the diagnosis and treatment of head and neck cancer in Japan. These guidelines are not intended to govern therapies that are not shown here, but rather aim to be used as a guide in searching for the most appropriate treatment for individual patient.
Authors: B Keam; J-P Machiels; H R Kim; L Licitra; W Golusinski; V Gregoire; Y G Lee; C Belka; Y Guo; S J Rajappa; M Tahara; M Azrif; M K Ang; M-H Yang; C-H Wang; Q S Ng; W I Wan Zamaniah; N Kiyota; S Babu; K Yang; G Curigliano; S Peters; T W Kim; T Yoshino; G Pentheroudakis Journal: ESMO Open Date: 2021-11-26
Authors: Nicole L Stout; Daniel Santa Mina; Kathleen D Lyons; Karen Robb; Julie K Silver Journal: CA Cancer J Clin Date: 2020-10-27 Impact factor: 508.702